News

Technology News

Aminex Thera Clears Series A Funding

Thursday, November 12, 2015 5:02:00 AM PDT | VentureDeal
   Kirkland, Washington  --  Pharmaceutical developer Aminex Therapeutics has secured $4 million in Series A venture capital funding.

Aminex is developing a new subclass of cancer immunotherapies called suppressor cell  modulators (SCMs).

The firm's lead candidate, AMX-513, promises to enable the body's immune system to attack cancer and its ability to spread.

Investors in the round were not disclosed by the company.

The company said it would use the proceeds to finalize preclinical testing for its AMX-513 candidate.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1